SPY323.50+0.86 0.27%
DIA268.10+0.52 0.19%
IXIC10,672.27+39.28 0.37%

Imara Receives Orphan Drug Designation From European Commission For IMR-687 For Treatment Of Sickle Cell Disease

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare

Benzinga · 08/25/2020 11:02

BOSTON, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the European Commission granted Orphan Drug designation to IMR-687 for the treatment of patients with sickle cell disease (SCD). IMR-687 has previously been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCD.